UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 174 filers reported holding UNIQURE NV in Q1 2023. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $307 | -93.1% | 45,737 | -88.2% | 0.00% | -91.7% |
Q2 2023 | $4,459 | -52.3% | 388,065 | -16.4% | 0.04% | -53.2% |
Q1 2023 | $9,349 | +41.3% | 464,217 | +59.0% | 0.08% | -19.8% |
Q4 2022 | $6,617 | -99.8% | 291,887 | +72.0% | 0.10% | +128.6% |
Q3 2022 | $3,183,000 | +90.1% | 169,673 | +88.9% | 0.04% | +100.0% |
Q2 2022 | $1,674,000 | +133.1% | 89,831 | +159.3% | 0.02% | +200.0% |
Q4 2021 | $718,000 | -23.7% | 34,637 | +17.9% | 0.01% | -46.2% |
Q3 2021 | $941,000 | -61.7% | 29,390 | -63.2% | 0.01% | -51.9% |
Q2 2021 | $2,458,000 | +520.7% | 79,810 | +578.5% | 0.03% | +350.0% |
Q1 2021 | $396,000 | -45.2% | 11,762 | -41.2% | 0.01% | -14.3% |
Q4 2020 | $722,000 | +85.1% | 19,990 | +88.9% | 0.01% | -12.5% |
Q3 2020 | $390,000 | -87.9% | 10,583 | -85.2% | 0.01% | -90.5% |
Q2 2020 | $3,220,000 | +1300.0% | 71,469 | +1121.9% | 0.08% | +950.0% |
Q3 2019 | $230,000 | -89.3% | 5,849 | -78.6% | 0.01% | -90.6% |
Q2 2019 | $2,140,000 | – | 27,389 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aquilo Capital Management, LLC | 841,471 | $15,786,000 | 5.69% |
Nantahala Capital Management | 2,901,929 | $54,440,000 | 3.52% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 544,500 | $10,209,000 | 3.27% |
683 Capital Management, LLC | 1,373,600 | $25,768,000 | 1.99% |
PFM Health Sciences, LP | 2,393,311 | $44,899,000 | 1.62% |
Integral Health Asset Management, LLC | 433,000 | $8,123,000 | 1.58% |
Privium Fund Management B.V. | 238,998 | $4,283,000 | 1.56% |
Nantahala Capital Management | 1,000,000 | $18,760,000 | 1.21% |
Henry James International Management Inc. | 89,469 | $1,678,000 | 0.94% |
Altium Capital Management LP | 105,000 | $1,970,000 | 0.72% |